Urinary estrogen metabolites, prostate specific antigen, and body mass index among African-American men in South Carolina

Cancer Detection and Prevention

Volumn 29, Issue 6, 2005, Pages 494-500

  Teas, Jane ^a,b   Cunningham, Joan E ^a,b   Fowke, Jay H ^c,d   Nitcheva, Daniela ^a,b   Kanwat, C P ^a,b   Boulware, R J ^e   Sepkovic, Daniel W ^f,g   Hurley, Thomas G ^a,b   Hebert, James R ^a,b,h  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b South Carolina Cancer Center   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e Palmetto Richland Memorial Hospital   (United States)

^f HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^g RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^h MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

African American men; Body mass index; Cancer history; Prostate cancer risk; PSA; Self reporting; Serum estradiol; Urinary estrogen metabolites

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 HYDROXYESTRONE; ESTROGEN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CANCER FAMILY; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC APPROACH ROUTE; DYNAMIC EXERCISE; ESTROGEN METABOLISM; ESTROGEN SYNTHESIS; ESTROGEN URINE LEVEL; HUMAN; LIFESTYLE; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; RISK ASSESSMENT; SCREENING TEST; SELF REPORT; SMOKING; STATISTICAL SIGNIFICANCE; URINALYSIS;

ADULT; AFRICAN AMERICANS; AGED; BODY MASS INDEX; ESTROGENS; HUMANS; HYDROXYESTRONES; MALE; MIDDLE AGED; PILOT PROJECTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SOUTH CAROLINA;

EID: 28844460759     PISSN: 0361090X     EISSN: 15251500     Source Type: Journal    
DOI: 10.1016/j.cdp.2005.08.004     Document Type: Article

References (70)

1. S. Reddy, M. Shapiro, R.J. Morton, and O.W. Brawley Prostate cancer in black and white Americans Cancer Metastat Rev 22 2003 83 86
2. P.A. Godley, A.P. Schenck, and M.A. Amamoo Racial differences in mortality among medicare recipients after treatment for localized prostate cancer J Natl Cancer Inst 95 2003 1702 1710
3. Centers for Disease Control: Cancer Prevention and Control South Carolina; 2004. http://www.cdc.gov/cancer/CancerBurden/sc.htm#prostate.
4. Centers for Disease Control: National Program of Cancer Registries 2000 Geographic area by sex and site; 2000. http://apps.nccd.cdc.gov/USCS/TableV.asp? group=2a&Year=2000&Gender=MAL&Var1=Cancer+of+the+Prostate.
5. V.L. Freeman, R. Durazo-Arvizu, A.M. Arozullah, and L.C. Keys Determinants of mortality following a diagnosis of prostate cancer in Veterans Affairs and private sector health care systems Am J Public Health 93 2003 1706 1712
6. E.D. Crawford Epidemiology of prostate cancer Urology 62 2003 3 12
7. N. Peters, and K. Armstrong Racial differences in prostate cancer treatment outcomes: a systematic review Cancer Nurs. 28 2005 108 118
8. C.D. Mullins, J.L.J. Cooke, and J. Wang Disparities in prevalence rates for lung, colorectal, breast, and prostate cancers in Medicaid J Natl Med Assoc 96 2004 809 816
9. G.C. Kabat, C.J. Chang, and J.A. Sparano Urinary estrogen metabolites and breast cancer: a case-control study Cancer Epidemiol Biomark Prev 6 1997 505 509
10. W. Zheng, L. Dunning, F. Jin, and J. Holtzman Correspondence re: GC Kabat et al., Urinary estrogen metabolites and breast cancer: a case-control study Cancer Epidemiol Biomark Prev 7 1998 85 86
11. A.L. Coker, M.M. Crane, J.A.P. Sticca, and D.W. Sepkovic Re: ethnic differences in estrogen metabolism in healthy women JNCI 89 1997 89 90
12. G.H. Ho, X.W. Luo, and C.Y. Ji Urinary 2/16alpha-hydroxyestrone ratio: correlation with serum insulin-like growth factor binding protein-3 and a potential biomarker of breast cancer risk Ann Acad Med Singapore 27 1998 294 299
13. E.N. Meilahn, B. de Stavola, and D.S. Allen Do urinary oestrogen metabolites predict breast cancer? Br J Cancer 78 1998 1250 1255
14. P. Muti, H.L. Bradlow, and A. Micheli Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16α-hydroxyestrone ratio in premenopausal and postmenopausal women Epidemiology 11 2000 635 640
15. J.H. Fowke, D. Qi, and H.L. Bradlow Urinary estrogen metabolites and breast cancer: differential pattern of risk found with pre-versus post-treatment collection Steroids 68 2003 65 72
16. G. Ursin, S. London, and F. Stanczyk Urinary 2-hydroxyestrone/16α- hydroxyestrone ratio and risk of breast cancer in postmenopausal women J Natl Cancer Inst 91 1999 1067 1072
17. G. Ursin, M. Wilson, and B.E. Henderson Do urinary estrogen metabolites reflect the differences in breast cancer risk between Singapore Chinese and United States African-American and white women? Cancer Res 15 2001 3326 3329
18. G. Ursin, S. London, and D. Yang Urinary 2-hydroxyestrone/16alpha- hydroxyestrone ratio and family history of breast cancer in premenopausal women Breast Cancer Res Treatment 72 2002 139 143
19. H.L. Bradlow, N.T. Telang, D.W. Sepkovic, and M.P. Osborne 2-Hydroxyestrone: the 'good' estrogen J Endocrinol 150 1996 259 265
20. H.L. Bradlow, R.J. Hershcopf, C.P. Martucci, and J. Fishman Estradiol 16alpha-hydroxylation in the mouse correlates with mammary tumor incidence and presence of murine mammary tumor virus: a possible model for the hormonal etiology of breast cancer in humans Proc Natl Acad Sci U S A 82 1985 6295 6299
21. J. Schneider, D. Kinne, and A. Fracchia Abnormal oxidative metabolism of estradiol in women with breast cancer Proc Natl Acad Sci U S A 79 1982 3047 3051
22. N.T. Telang, A. Suto, and G.Y. Wong Induction by estrogen metabolite 16alpha-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells J Natl Cancer Inst 84 1992 634 638
23. M. Gupta, A. McDougal, and S. Safe Estrogenic and antiestrogenic activities of 16alpha- and 2-hydroxy metabolites of 17beta-estradiol in MCF-7 and T47D human breast cancer cells J Steroid Biochem Mol Biol 67 1998 413 419
24. B.T. Zhu, and A.H. Conney Functional role of estrogen metabolism in target cells: review and perspectives Carcinogenesis 19 1998 1 27
25. J.S. Lewis, T.J. Thomas, and C.M. Klinge Regulation of cell cycle and cyclins by 16alpha-hydroxyestrone in MCF-7 breast cancer cells J Mol Endocrinol 27 2001 293 307
26. H.L. Bradlow, D.W. Sepkovic, and N.T. Telang Osborne MP: multifunctional aspects of the action of indole-3-carbinol as an antitumor agent Ann NY Acad Sci 889 1999 204 213
27. W. de Ronde, H.A. Pols, J.P. van Leeuwen, and F.H. de Jong The importance of oestrogens in males Clin Endocrinol (Oxf) 58 2003 529 542
28. M.E. Taplin, and S.M. Ho Clinical review 134: the endocrinology of prostate cancer J Clin Endocrinol Metab 86 2001 3467 3477
29. E. Barrett-Connor, C. Garland, and J.B. McPhillips A prospective, population-based study of androstenedione, estrogens, and prostatic cancer Cancer Res 50 1990 169 173
30. A.W. Hsing, and G.W. Comstock Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer Cancer Epidemiol Biomark Prev 2 1993 27 32
31. J.F. Dorgan, D. Albanes, and J. Virtamo Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland Cancer Epidemiol Biomark Prev 7 1998 1069 1074
32. C. Chen, N.S. Weiss, and F.Z. Stanczyk Endogenous sex hormones and prostate cancer risk: a case-control study nested within the carotene and retinol efficacy trial Cancer Epidemiol Biomark Prev 12 2003 1410 1416
33. A. Nomura, L.K. Heilbrun, G.N. Stemmermann, and H.L. Judd Prediagnostic serum hormones and the risk of prostate cancer Cancer Res 48 1988 3515 3517
34. P. Muti, K. Westerlind, and T. Wu Urinary estrogen metabolites and prostate cancer: a case-control study in the United States Cancer Causes Control 13 2002 947 955
35. E. Giovannucci, E.B. Rimm, and Y. Liu A prospective study of cruciferous vegetables and prostate cancer Cancer Epidemiol Biomark Prev 12 2003 1403 1409
36. A.R. Kristal, and W. LJ Brassica vegetables and prostate cancer risk: a review of the epidemiological evidence Nutr Cancer 42 2002 1 9
37. J. Fishman, H.L. Bradlow, and J. Schneider Radiometric analysis of biological oxidations in man: sex differences in estradiol metabolism Proc Natl Acad Sci U S A 77 1980 4957 4960
38. H. Adlercreutz, S.L. Gorbach, and B.R. Goldin Estrogen metabolism and excretion in oriental and caucasion women JNCI 86 1994 1076 1082
39. E. Taioli, S.J. Garte, and J. Trachman Ethnic differences in estrogen metabolism in healthy women J Natl Cancer Inst 88 1996 617
40. E. Taioli, F. Crofts, and J. Trachman Radical differences in CYP1A1 genotype and function Toxicol Lett 77 1995 357 362
41. C.E. Matthews, J.H. Fowke, and Q. Dai Physical activity, body size, and estrogen metabolism in women Cancer Causes Control 15 2004 473 481
42. A. Engeland, S. Tretli, and T. Bjorge Height, body mass index, and prostate cancer: a follow-up of 950,000 Norwegian men Br J Cancer 89 2003 1237 1242
43. C. Rodriguez, A.V. Patel, and E.E. Calle Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States Cancer Epidemiol Biomark Prev 10 2001 345 353
44. S.J. Freedland, W.J. Aronson, and C.J. Kane Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group J Clin Oncol 22 2004 446 453
45. A. Tchernof, J.P. Despres, and A. Belanger Reduced testosterone and adrenal C19 steroid levels in obese men Metabolism 44 1995 513 519
46. F.S. Greenspan, and G.J. Strewler Basic and clinical endocrinology 1997 Appleton & Lange Stamford, CT
47. SCDHEC Healthy people living in healthy communities 2004 South Carolina Department of Health and Environmental Control Columbia p. 70
48. J.H. Fowke, X.O. Shu, and Q. Dai Oral contraceptive use and breast cancer risk: modification by NAD(P)H:quinone oxoreductase (NQO1) genetic polymorphisms Cancer Epidemiol Biomark Prev 13 2004 1308 1315
49. T.A. Stamey, M. Caldwell, and J.E. McNeal The prostate specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years? J Urol 172 2004 1297 1301
50. A.W. Partin, J.E. Oesterling, and J.I. Epstein Influence of age and endocrine factors on the volume of benign prostatic hyperplasia J Urol 145 1991 405 409
51. J.J. Michnovicz, and R.A. Galbraith Effects of exogenous thyroxine on C-2 and C-16alpha hydroxylations of estradiol in humans Steroids 55 1990 22 26
52. J.J. Michnovicz, and R.A. Galbraith Cimetidine inhibits catechol estrogen metabolism in women Metabolism 40 1991 170 174
53. M.C. Weinrich, S.J. Jacobsen, and S.P. Weinrich Reference ranges for serum prostate-specific antigen in black and white men without cancer Urology 52 1998 967 973
54. T.L. Klug, H.L. Bradlow, and D.W. Sepkovic Monoclonal antibody based enzyme immunoassay for simultaneous quantitation of 2 and 16α- hydroxyestrone in urine Steroids 59 1994 648 655
55. H.L. Bradlow, D.W. Sepkovic, T. Klug, and M.P. Osborne Application of an improved ELISA assay to the analysis of urinary estrogen metabolites Steroids 63 1998 406 413
56. R.G. Ziegler, S.C. Rossi, and T.R. Fears Quantifying estrogen metabolism: an evaluation of the reproducibility and validity of enzyme immunoassays for 2-hydroxyestrone and 16α-hydroxyestrone in urine Environ Health Perspect 105 1997 607 614
57. R.T. Falk, S.C. Rossi, and T.R. Fears A new ELISA kit for measuring 2-hydroxyestrone, 16-hydroxyestrone and their ratio: reproducibility, validity and assay performance after freeze-thaw cycling and preservation by boric acid Cancer Epidemiol Biomark Prev 9 2000 81 87
58. D.S. Michaud, J.E. Manson, and D. Spriegelman Reproducibility of plasma and urinary sex hormone levels in premenopausal women over a one-year period Cancer Epidemiol Biomark Prev 8 1999 1059 1064
59. B.R. Grzedaa, T.L. Bui, and C.N. Warner Measurement of prostate-specific antigen by use of a novel blood collection and analytical system Clin Chem 48 2002 1272 1278
60. DHEC S. South Carolina behavioral risk factors surveillance system report: 2001 survey results. Columbia: South Carolina; 2001.
61. J. Schneider, H.L. Bradlow, and G. Strain Effects of obesity on estradiol metabolism: decreased formation of nonuterotropic metabolites J Clin Endocrinol Metabol 56 1983 973 978
62. F. Bianchini, R. Kaaks, and H. Vainio Overweight, obesity, and cancer risk Lancet Oncol 9 2002 565 574
63. R.T. Falk, T.R. Fears, and X. Xu Urinary estrogen metabolites and their ratio among Asian-American women Cancer Epidemiol Biomark Prev 14 2005 221 226
64. P.M. Kroonenberg, T. Murakami, and J.W. Coebergh Added value of three-way methods for the analysis of mortality trends illustrated with worldwide female cancer mortality Stat Meth Med Res 11 2002 275 292
65. C. Zeigler-Johnson, T. Friebel, and A.H. Walker CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer Cancer Res 64 2004 8461 8467
66. J. Baillargeon, B.H. Pollock, and A.R. Kristal The association of body mass index and prostate-specific antigen in a population-based study Cancer 103 2005 1092 1095
67. J.C.J. Presti, U. Lee, J.D. Brooks, and M.K. Terris Lower body mass index is associated with a higher prostate cancer detection rate and less favorable pathological features in a biopsy population J Urol 171 2004 2199 2202
68. J.J.V.I. Thompson, D.K. Pauler, and P.J. Goodman Prevalence of prostate cancer among men with a prostate-specific antigen level less than/equal 4.0 ng per milliliter New England J Med 350 2004 2239 2246
69. DJTEC SCHD. Prevalence of overweight and obesity for 1990-2001 by race and sex. SC Department of Health and Environmental Concerns; 2003.
70. H.B. Carter Prostate cancers in men with low PSA levels - Must we find them? New England J Med 350 2004 2292 2294